138 related articles for article (PubMed ID: 20037789)
1. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer.
Hashimoto K; Takashima A; Nagashima K; Okazaki SS; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shimada Y
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1059-64. PubMed ID: 20037789
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Chung IJ
Gastric Cancer; 2011 Aug; 14(3):249-56. PubMed ID: 21431297
[TBL] [Abstract][Full Text] [Related]
3. Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis.
Iizumi S; Takashima A; Sakamaki K; Morita S; Boku N
Cancer Chemother Pharmacol; 2018 Jun; 81(6):981-989. PubMed ID: 29600386
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.
Fanotto V; Uccello M; Pecora I; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Ferrari L; Bordonaro R; Vivaldi C; Gerratana L; Bozzarelli S; Filippi R; Bilancia D; Russano M; Aprile G
Oncologist; 2017 Dec; 22(12):1463-1469. PubMed ID: 28860412
[TBL] [Abstract][Full Text] [Related]
5. Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
Sano A; Sohda M; Hosoi N; Tateno K; Watanabe T; Uchida S; Nakazawa N; Osone K; Okada T; Shiraishi T; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Nov; 43(11):5205-5213. PubMed ID: 37909978
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
[TBL] [Abstract][Full Text] [Related]
7. Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world.
Takashima A; Iizumi S; Boku N
Jpn J Clin Oncol; 2017 Jul; 47(7):583-589. PubMed ID: 28398526
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.
Fanotto V; Cordio S; Pasquini G; Fontanella C; Rimassa L; Leone F; Rosati G; Santini D; Giampieri R; Di Donato S; Tomasello G; Silvestris N; Pietrantonio F; Battaglin F; Avallone A; Scartozzi M; Lutrino ES; Melisi D; Antonuzzo L; Pellegrino A; Torri V; Aprile G
Gastric Cancer; 2017 Sep; 20(5):825-833. PubMed ID: 28028664
[TBL] [Abstract][Full Text] [Related]
10. Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial.
Nishikawa K; Murotani K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Hasegawa H; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2020 Jun; 132():159-167. PubMed ID: 32380427
[TBL] [Abstract][Full Text] [Related]
11. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Takahari D; Boku N; Mizusawa J; Takashima A; Yamada Y; Yoshino T; Yamazaki K; Koizumi W; Fukase K; Yamaguchi K; Goto M; Nishina T; Tamura T; Tsuji A; Ohtsu A
Oncologist; 2014 Apr; 19(4):358-66. PubMed ID: 24668328
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
Arai H; Kawahira M; Yasui H; Masuishi T; Muro K; Nakajima TE
Int J Clin Oncol; 2021 Feb; 26(2):355-363. PubMed ID: 33063177
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
14. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
Wang Z; Zhang L; Wang J; Wang Y; Dong Q; Piao H; Wang Q; Zhang J
J Immunol Res; 2020; 2020():6813176. PubMed ID: 32832571
[TBL] [Abstract][Full Text] [Related]
15. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
16. Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer.
Bohanes P; Courvoisier DS; Perneger TV; Morel P; Huber O; Roth AD
Swiss Med Wkly; 2011; 141():w13249. PubMed ID: 21870299
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center.
Sirohi B; Rastogi S; Dawood S; Talole S; Ramadwar M; Shetty N; Shrikhande SV
Med Oncol; 2014 Oct; 31(10):138. PubMed ID: 25228200
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Hwang JE; Hong JY; Kim JE; Shim HJ; Bae WK; Hwang EC; Jeong O; Park YK; Lee KH; Lee JH; Cho SH; Chung IJ
Jpn J Clin Oncol; 2015 Jun; 45(6):541-6. PubMed ID: 25759484
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
20. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
Yun J; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
Eur J Cancer; 2010 Mar; 46(5):885-91. PubMed ID: 20060288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
